|
16/01/2025
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
15/01/2025
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
14/01/2025
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
13/01/2025
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
13/01/2025
|
07:00
|
GSK enters agreement to acquire IDRx, Inc.
|
RNS
|
|
10/01/2025
|
07:00
|
Shingrix fully liquid accepted for US FDA review
|
RNS
|
|
07/01/2025
|
07:00
|
GSK ADC gets FDA breakthrough therapy designation
|
RNS
|
|
03/01/2025
|
07:00
|
GSK’s Nucala approved in China for use in CRSwNP
|
RNS
|
|
02/01/2025
|
15:00
|
Total Voting Rights
|
RNS
|
|
23/12/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
20/12/2024
|
09:00
|
Block Listing Application
|
RNS
|
|
20/12/2024
|
07:00
|
Headline results from phase III FIRST trial
|
RNS
|
|
16/12/2024
|
07:11
|
Jemperli receives US FDA breakthrough designation
|
RNS
|
|
16/12/2024
|
07:05
|
EMA grants PRIME Designation for GSK’227
|
RNS
|
|
16/12/2024
|
07:00
|
Jemperli receives positive CHMP opinion
|
RNS
|
|
12/12/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
09/12/2024
|
18:29
|
Overall survival data presented for Blenrep
|
RNS
|
|
09/12/2024
|
07:05
|
Blenrep combination China filing acceptance
|
RNS
|
|
09/12/2024
|
07:00
|
Nucala COPD submission accepted by US FDA
|
RNS
|
|
05/12/2024
|
07:00
|
Zhifei China collaboration revised and extended
|
RNS
|
|
02/12/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
02/12/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
27/11/2024
|
07:00
|
GSK liquid meningitis vaccine authorised in EU
|
RNS
|
|
25/11/2024
|
07:00
|
Blenrep combinations accepted for US FDA review
|
RNS
|
|
22/11/2024
|
07:00
|
Japan approves first RSV vaccine for adults 50-59
|
RNS
|
|
19/11/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
19/11/2024
|
07:00
|
GLISTEN Trial of Linerixibat Meets Endpoint
|
RNS
|
|
14/11/2024
|
07:00
|
GSK announces overall survival results for Blenrep
|
RNS
|
|
13/11/2024
|
15:00
|
Block listing Interim Review
|
RNS
|
|
12/11/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
11/11/2024
|
15:01
|
GSK publishes provisional 2025 dividend dates
|
RNS
|
|
01/11/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
30/10/2024
|
14:29
|
Director/PDMR Shareholding
|
RNS
|
|
30/10/2024
|
07:00
|
3rd Quarter Results
|
RNS
|
|
24/10/2024
|
07:00
|
New positive Arexvy data in younger adults at risk
|
RNS
|
|
17/10/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
16/10/2024
|
16:09
|
Director/PDMR Shareholding
|
RNS
|
|
16/10/2024
|
07:00
|
FDA accepts new drug application for gepotidacin
|
RNS
|
|
14/10/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
14/10/2024
|
07:00
|
Positive results of ANCHOR trials of depemokimab
|
RNS
|
|
11/10/2024
|
15:33
|
Director/PDMR Shareholding
|
RNS
|
|
10/10/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
09/10/2024
|
17:48
|
Zantac (ranitidine) litigation settlements
|
RNS
|
|
08/10/2024
|
11:45
|
Positive efficacy data of Arexvy over 3 seasons
|
RNS
|
|
01/10/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
24/09/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
24/09/2024
|
07:00
|
Positive EU opinion for GSK liquid Menveo vaccine
|
RNS
|
|
18/09/2024
|
13:20
|
Statement: Zantac (ranitidine) litigation
|
RNS
|
|
17/09/2024
|
07:00
|
Japan Filing Acceptance: Blenrep Multiple Myeloma
|
RNS
|
|
13/09/2024
|
07:00
|
China Breakthrough Therapy Designation for Blenrep
|
RNS
|